Company Overview and News

25
Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

2018-10-17 channelnewsasia
Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers.
ATHTF REGN AMGN TEVA TEVVF ANTM SNY TEVJF GCVRZ NVS SAN CI SNYNF ANTX

25
Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

2018-10-17 reuters
LOS ANGELES (Reuters) - Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers.
ATHTF REGN AMGN TEVA TEVVF ANTM SNY TEVJF GCVRZ NVS SAN CI SNYNF ANTX

25
Exclusive: Express Scripts covers Amgen, Lilly migraine therapies, excludes Teva drug

2018-10-17 channelnewsasia
LOS ANGELES: Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but is excluding a rival medication made by Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers.
ATHTF REGN AMGN TEVA TEVVF ANTM SNY TEVJF GCVRZ NVS SAN CI SNYNF ANTX

2
UPDATE 1-Sanofi, Regeneron skin cancer drug gets FDA nod

2018-09-28 reuters
Sept 28 (Reuters) - Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.
REGN GCVRZ SAN SNYNF SNY

2
Sanofi, Regeneron skin cancer drug gets FDA nod

2018-09-28 channelnewsasia
Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.
REGN GCVRZ SAN SNYNF SNY

2
Sanofi, Regeneron skin cancer drug gets FDA nod

2018-09-28 reuters
(Reuters) - Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration.
REGN GCVRZ SAN SNYNF SNY

2
Vectura Group plc: Interim Results

2018-09-11 globenewswire
Chippenham, UK - 11 September 2018: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") announces its unaudited Interim Results for the six months ended 30 June 2018 and reiterates its current guidance for the full year.
11IE BCS OIL 42KM SNY 83SF VEC 83SK GCVRZ 42MA SAN SNYNF VEGPF 47MC

3
Amicus sets US$315,000 price for new Fabry disease treatment - Channel NewsAsia

2018-08-13 channelnewsasia
REUTERS: Amicus Therapeutics priced its new Fabry disease treatment at an average US$315,000 per year in the United States, the company said on Monday.
GCVRZ FOLD SAN SNYNF SNY

4
Amicus sets $315,000 price for new Fabry disease treatment

2018-08-13 reuters - 1
(Reuters) - Amicus Therapeutics priced its new Fabry disease treatment at an average $315,000 per year in the United States, the company said on Monday.
GCVRZ FOLD SAN SNYNF SNY

3
UPDATE 2-Amicus Therapeutics receives U.S. approval for Fabry disease drug

2018-08-11 reuters
(Reuters) - U.S. health regulators on Friday approved Amicus Therapeutics’ Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.
GCVRZ FOLD SAN SNYNF SNY

2
Sanofi Has Been Stockpiling Drugs for No-Deal Brexit for Six Months - WSJ

2018-07-31 wsj
French pharmaceuticals company Sanofi SA has been making drug-shortage contingency plans for more than a year to prepare for the U.K. failing to reach a deal with the European Union on Brexit, according to a person familiar with the matter.
GCVRZ SAN SNYNF SNY

2
Pfizer Raises Prices of 40 Drugs, Some by Nearly 10%

2018-07-03 biospace
In May President Donald Trump predicted a “massive drops” in drug prices following the signing of the Right-to-Try legislation, as well as a Health and Human Services initiative he called “the most sweeping action in history” to lower the cost of prescription drug prices.
GCVRZ SAN SNYNF SNY

135
Mylan Stock Looks Cheap, but Don’t Overlook These Risks

2018-06-21 investorplace
Mylan N.V. (NASDAQ:MYL) has been a battleground stock in 2018. And that’s with good reason, Mylan stock has seen plenty of good news, but also a number of setbacks. EpiPen is a perfect example. The brand brought Mylan shame and a substantial fine, but it’s also in short supply now, continuing to lead to strong ongoing profits.
MYL TEVJF GCVRZ TEVA TEVVF SAN SNYNF GSK SNY

109
3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

2018-06-14 investorplace - 1
In spite of a strong start in 2018, the pharma/biotech industry is struggling currently, presumably due to a shift in focus to lowering of high drug prices and faster approval of generics. Moreover, quite a few negative pipeline and regulatory updates announced this year so far have probably had an unfavorable impact on the industry.
CELGZ AZN IPXL GSK SNY SHPG MRK GCVRZ CELG NVS SAN SNYNF

70
5 Biotech Stocks to Boost Your Portfolio’s Health This Year

2018-05-31 investorplace
Though the drug sector was off to a strong start in 2018, it has struggled thereafter probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Moreover, concerns about pressure on drug prices continue to cloud shares of pharma and biotech companies.
CELGZ IPXL GCVRZ CELG CRSP SAN SNYNF SNY AMRX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:SAN / SANOFI on message board site Silicon Investor.

Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Sandstorm Gold Sandstorm Gold Sandstorm Gold
Monsanto (MON) : Valuation and Ethics of BioEngineering Monsanto (MON) : Valuation and Ethics of BioEngineering Monsanto (MON) : Valuation and Ethics of BioEngineering WDC/Sandisk Corporation WDC/Sandisk Corporation WDC/Sandisk Corporation
Sangamo BioSciences, Inc. SGMO Sangamo BioSciences, Inc. SGMO Sangamo BioSciences, Inc. SGMO Bernie Sanders 2016 Bernie Sanders 2016 Bernie Sanders 2016
Las Vegas Sands Corp. (LVS) Las Vegas Sands Corp. (LVS) Las Vegas Sands Corp. (LVS) Bernie Sanders Comedy Message Board 2016 Bernie Sanders Comedy Message Board 2016 Bernie Sanders Comedy Message Board 2016
Bill Clinton Scandal - SANITY CHECK Bill Clinton Scandal - SANITY CHECK Bill Clinton Scandal - SANITY CHECK CLL oilsands play CLL oilsands play CLL oilsands play